Study M1051
Study name | Hue JJ 2022 |
Title | IDO1 is a therapeutic target for pancreatic cancer-associated depression |
Overall design | The aim of this study was to explore the role of indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme important in the conversion of tryptophan to kynurenine, in a murine model of pancreatic cancer-associated depression. For the pancreatic cancer-associated depression model, murine pancreatic cancer cells were injected into the pancreas of mice. Epacadostat, an IDO1 inhibitor, was used to improve pancreatic cancer-associated depression. C57BL/6J mice were divided into the following 3 groups: (1) control group (non-tumor-bearing with vehicle treatment), (2) tumor-bearing group (tumor-bearing with vehicle treatment), and (3) tumor-bearing + epacadostat group (tumor-bearing with epacadostat treatment). Mice underwent behavioral testing at baseline and between 5-6 weeks after tumor implantation. Tumor-bearing mice treated with epacadostat (50 mg/kg, once daily via oral gavage) exhibited improved mood relative to mice receiving vehicle. Blood was extracted after 4 weeks of tumor growth for comparisons between tumor-bearing and non-tumor-bearing mice. For tumor-bearing mice undergoing treatment, blood was collected after completion of behavioral studies (i.e., 6-7 weeks after tumor implantation). Metabolic profiles in the serum were compared using LC-MS. |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Mouse; C57BL/6J mouse; |
Categories of depression | Animal model; Other animal model; Other animal model; |
Criteria for depression | Forced swimming test, tail suspension test |
Sample size | 17 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: Prominence HPLC system (Shimadzu) with 5500 QTRAP hybrid quadrupole mass spectrometer (AB/SCIEX); |
PMID | |
DOI | |
Citation | Hue JJ, Graor HJ, Zarei M, et al. IDO1 is a therapeutic target for pancreatic cancer-associated depression. Mol Cancer Ther. 2022 Dec 2;21(12):1810-1822. |
Metabolite |
